|
APUS Apimeds Pharmaceuticals US Inc 1894525 |
| Income Statement |
|
Net Income
|
2026-03-31
|
$-35,059,852.00 |
| Balance Sheet |
|
Current Assets
|
$13,153,203.00 |
|
Assets
|
$141,219,157.00 |
|
Current Liabilities
|
$14,584,883.00 |
|
Liabilities
|
$14,703,698.00 |
|
Equity
|
$126,515,459.00 |
|
Shares Out
|
12575983.00 |
| Cash Flow Statement |
|
Operating Cash Flow
|
$-2,067,727.00 |
|
Investing Cash Flow
|
$490,606.00 |
| Market Analysis |
Market Cap
|
$61,873,836.36 |
|
Price
|
$4.93 |
|
BVPS
|
10.06 |
|
PB
|
0.49 |
|
EPS
|
-2.26 |
|
FCF
|
$-2,077,121.00 |
|
| Dividends |
|
Dividend Data Last Updated
|
2026-08-01 09:31:43 |
|
|
| Earnings |
|
Earnings Last Updated
|
2026-08-03 10:01:43 |
|
|
|
Find a discrepancy? The most accurate way to find company fundamental data is to view APUS documents filed with the SEC.
APUS Filings
Clear
